The investigational oral therapy APT-101 was well tolerated and reduced fibrosis, or scarring, in a mouse model of systemic sclerosis (SSc), according to a recent presentation from the therapy’s developer, Apie Therapeutics.
Apie is developing APT-101 to treat interstitial lung disease (ILD), a term that encompasses a group of disorders marked by significant fibrosis and inflammation of the lungs. Patients with SSc often develop ILD as their disease progresses.
According to Apie, the company is on track to file an application with the U.S. Food and Drug Administration (FDA) to begin a clinical testing program for SSc patients, including those with ILD.
Continue reading here.
Comments are closed.
Scleroderma Queensland Support Group